Abstract
With global progress towards malaria reduction stalling, further analysis of the epidemiology is required, particularly in countries with the highest burden. National surveys have mostly analysed infection prevalence, while large-scale data on parasite density and different developmental forms are rarely available. In Nigeria, the country with the largest burden globally, blood slide microscopy of children up to five years of age was conducted in the 2018 National Demographic and Health Survey, and infection prevalence previously reported. In the current study, malaria parasite density measurements are reported and analysed for 7783 of the children sampled across the 36 states within the six geopolitical zones of the country, with asexual and sexual stages considered separately and comparisons of infections with different malaria parasite species being performed. Across all states of Nigeria, there was a positive correlation between mean asexual parasite density in peripheral blood of infected individuals and prevalence of infection in the community (Spearman’s rho = 0.39, P = 0.02). Asexual parasite densities were highest in the northern geopolitical zones (geometric means > 2000 μL-1), extending the evidence of exceptionally high infection burden in many areas. Sexual parasite prevalence in each state was highly correlated with asexual parasite prevalence (Spearman’s rho = 0.70, P < 0.001), although sexual parasite densities were low (geometric means < 100 μL-1 in all zones). Infants had lower parasite densities than children above one year of age, but there were no differences between male and female children. Most infections were of P. falciparum, which had higher asexual densities but lower sexual parasite densities than P. malariae or P. ovale mono-infections. However, mixed species infections had the highest asexual parasite densities. It is recommended that future large surveys in high burden countries measure parasite densities as well as developmental stages and species, to improve the quality of malaria epidemiology and tracking of future changes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Institutional funding supported investigators' time, including support of W.O. and Ol.Ol. by the College of Medicine, University of Lagos, support of P.U., N.O., C.O., F.O., A.M., and E.S. by the Federal Ministry of Hethth, Nigeria, and support of D.J.C. by MRC grant MR/S009760/1 and the London School of Hygiene and Tropical Medicine.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All the samples were collected as part of the 2018 Nationwide Multiple Indicator Cluster Survey (MICS), under the Demographic and Health Surveys (DHS) Programme (https://dhsprogram.com/). Procedures for the surveys were reviewed and approved by the ICF Institutional Review Board (IRB), and by the National Health Research Ethics Committee of Nigeria (NHREC). Informed consent was obtained from all subjects or their legal guardians in the case of the children sampled for this analysis. The parasitological data generated from the microscopical analyses were merged with the anonymised demographic data from the same samples as provided by the MICS database (http://mics.unicef.org/surveys), with approval from the Ethics Committee of the London School of Hygiene and Tropical Medicine.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data generated or analysed during this study are included in this manuscript and its supplementary information files.
